FDA
-
-
-
-
-
-
-
Aethlon Medical Announces Pricing of $4.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules
-
-
-
-
-
-
-
Aethlon Medical Monitoring Current Ebola Outbreak and Reaffirms Outbreak/Pandemic Preparedness
-
-
-
-
-
-
-
Aethlon Medical Announces Financial Results for the Fiscal Fourth Quarter Ended March 31, 2025, and Provides Corporate Update
-
-
-
-
-
-
-
Aethlon Medical Announces Financial Results for the Fiscal Third Quarter Ended December 31, 2024 and Provides Corporate Update
-
-
-
-
-
-
-
Aethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update
-
-
-
-
-
-
-
Aethlon Receives Ethics Committee Approval for Hemopurifier® Cancer Trial in India
-
-
-
-
-
-
-
Aethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Extracellular Vesicles and microRNAs from Renal Perfusates Following Controlled Oxygenated Rew
-
331,677 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

